Gene expression panel for prognosis of prostate cancer recurrence
Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual. Systems are also provided for predicting progression and/or recurrence of PCa.
1. A method for treating a patient with prostate cancer, the method comprising:
obtaining a biological sample from the patient, wherein the biological sample comprises a prostate tissue sample,
detecting expression levels of a collection of genes from the biological sample, wherein detecting expression levels of the collection of genes comprises hybridizing probes specific for each of the genes to nucleic acid molecules derived from the biological sample, wherein the collection of genes comprises a collection of signature genes, and
wherein said collection of signature genes comprises NKX2-1 and ABCC11;
correlating expression levels of said collection of signature genes with prostate-cancer related mortality to identify whether the patient is at risk of prostate-cancer related mortality; and
treating a patient at risk of prostate-cancer related mortality with one or more of radical prostatectomy, brachytherapy of the prostate, radiotherapy of the prostate, neoadjuvant hormone therapy for treating prostate cancer, and adjuvant hormone therapy for treating prostate cancer.
2. The method of claim 1 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, EDARADD, GPR81, MYBPC1, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, and NPR3.
3. The method of claim 1 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, and PGC.
4. The method of claim 1 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: ZYG11A, MMP11, MYBPC1, DUOX1, EDARADD, PGC, GPR81, and ABLIM1.
5. The method of claim 1 , wherein the expression levels of a collection of signature genes comprise gene expression levels measured at multiple times.
6. The method of claim 1 , wherein detecting the expression levels comprises:
obtaining expressed nucleic acids from the biological sample; and
determining amounts of the expressed nucleic acids for sequences of the signature genes.
7. The method of claim 6 , wherein determining the amounts of the expressed nucleic acids comprises performing quantitative PCR on nucleic acids having sequences of the expressed nucleic acids from the biological sample.
8. The method of claim 6 , wherein determining the amounts of the expressed nucleic acids comprises applying nucleic acids having sequences of the expressed nucleic acids from the biological sample to a nucleic acid array.
9. The method of claim 6 , wherein determining the amounts of the expressed nucleic acids comprises sequencing nucleic acids using a next generation sequencing technique.
10. The method of claim 6 , further comprising random priming of mRNA to produce cDNA.
11. The method of claim 10 , further comprising further comprising hybridizing the produced cDNA to oligonucleotides corresponding to the signature genes.
12. The method of claim 11 , further comprising extending the oligonucleotides.
13. The method of claim 12 , further comprising ligating the oligonucleotides.
14. The method of claim 13 , further comprising fluorescently labeling the oligonucleotides in qPCR and determining the expression levels of the signature genes based on fluorescence levels of the labeled oligonucleotides.
15. The method of claim 1 , further comprising microdissecting the prostate tissue sample using a laser capture microdissection.
16. The method of claim 1 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3.
17. The method of claim 1 , wherein said collection of signature genes comprises at least two additional genes selected from the group consisting of: ZYG11A, MMP11, MYBPC1, DUOX1, EDARADD, PGC, GPR81, and ABLIM1.
18. The method of claim 1 , wherein said collection of signature genes comprises at least three additional genes selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3, and NPR3.
19. The method of claim 1 , wherein said collection of signature genes comprises at least three additional genes selected from the group consisting of: UPK1A, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, EDARADD, GPR81, MYBPC1, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, and NPR3.
20. The method of claim 1 , wherein said collection of signature genes comprises at least three additional genes selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, and PGC.
21. The method of claim 1 , wherein said collection of signature genes comprises at least three additional genes selected from the group consisting of: ZYG11A, MMP11, MYBPC1, DUOX1, EDARADD, PGC, GPR81, and ABLIM1.
22. The method of claim 1 , wherein detecting expression levels of a collection of signature genes comprises contacting nucleic acid molecules derived from the biological sample with at least two probes, each configured to hybridize to a signature gene.
23. The method of claim 1 , wherein identifying whether the patient is at risk of prostate cancer-related mortality comprises determining the patient's risk of clinical recurrence of prostate cancer or the patient's risk of biochemical recurrence of prostate cancer or both.
24. The method of claim 1 , wherein the patient's clinical stage is T2.
25. A method for treating a patient with prostate cancer, wherein the patient has undergone a radical prostatectomy, the method comprising:
obtaining a biological sample from the patient, wherein the biological sample comprises a prostate tissue sample;
detecting expression levels of a collection of genes from the biological sample, wherein detecting expression levels of the genes comprises hybridizing probes specific for each of the genes to nucleic acid molecules derived from the biological sample, wherein the genes comprise a collection of signature genes, and
wherein said collection of signature genes comprises NKX2-1 and ABCC11;
correlating expression level of said collection of signature genes with clinical recurrence of prostate cancer after radical prostatectomy to identify whether the patient is at risk of clinical recurrence of prostate cancer after radical prostatectomy; and
treating a patient at risk of clinical recurrence of prostate cancer after radical prostatectomy with at least one of brachytherapy of the prostate, radiotherapy of the prostate, neoadjuvant hormone therapy for treating prostate cancer, and adjuvant hormone therapy for treating prostate cancer.
26. The method of claim 25 , wherein identifying whether the patient is at risk of clinical recurrence of prostate cancer comprises determining the patient's risk of biochemical recurrence of prostate cancer.
27. The method of claim 25 , wherein the patient's clinical stage is T2.
28. The method of claim 25 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3.
29. The method of claim 25 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, EDARADD, GPR81, MYBPC1, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, and NPR3.
30. The method of claim 25 , wherein said collection of signature genes comprises at least one additional gene selected from the group consisting of: UPK1A, ADRA2C, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, and PGC.
31. A method comprising detecting expression levels of genes from a biological sample taken from an individual, wherein the biological sample comprises a prostate tissue sample, wherein the genes consist of NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3.